Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
May 9, 2017
- Completed Enrollment in SAKURA 1 & 2 Phase 3 Pivotal Trials of RT002 for Glabellar Lines - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditio...
May 1, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that it is expanding the Company's Phase 2 program investigating the use of DaxibotulinumtoxinA ...
Apr 25, 2017
- Conference Call Scheduled for Tuesday, May 9, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will ...
Mar 7, 2017
SAKURA Program Topline Results on Track to Report Fourth Quarter 2017 NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of pa...
Mar 3, 2017
- Additional Presentation Affirms Use of Patient Questionnaires in Assessing Frown Lines - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today ...
Feb 27, 2017
- Cash and investments of $185.5 million as of December 31, 2016 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the fourth ...
Feb 22, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance managem...
Feb 16, 2017
- Conference Call Scheduled for Monday, February 27, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the...
Jan 26, 2017
- Poster Abstract at TOXINS 2017 Receives Honors - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the ...
Jan 18, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentations of clinical data for DaxibotulinumtoxinA Injectable (RT002) at TOXINS 2017, the Third Int...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Shareholder Tools